Summary: Zeiss and Mindpeak have joined forces to create an integrated multiplex immunofluorescence (mIF) solution, combining advanced imaging and AI-powered pathology tools to support research, diagnostics, and clinical applications.

Takeaways:

  1. Streamlined mIF Workflow: The partnership integrates Zeiss’ imaging instruments and Mindpeak’s AI-driven pathology algorithms to provide a comprehensive workflow from slide preparation to report generation.
  2. Broad Market Reach: The joint solution addresses research, diagnostic (Dx), companion diagnostic (CDx) development, and clinical routine applications, enhancing precision and efficiency in pathology.
  3. Commitment to Innovation: By merging Zeiss’ imaging expertise with Mindpeak’s AI analytics, the collaboration aims to improve reproducibility and advance personalized medicine initiatives in both research and clinical settings.

Zeiss announced a partnership with Mindpeak, a provider in AI-powered pathology solutions, to develop an integrated multiplex immunofluorescence (mIF) solution that serves pathologists across research, diagnostics, and clinical applications.

Developing an AI-Based Pathology Solution

Mindpeak’s expertise in AI-based image analysis of pathological tissues, particularly through its established algorithms for clinical routine applications, complements Zeiss’ instruments and software for research applications of mIF. The joint solution will integrate both companies’ existing offerings to enhance the value for the users and address multiple market segments, including:

  • Research: Providing advanced mIF tools for scientific exploration.
  • Diagnostic (Dx) and Companion Diagnostic (CDx) Development: Empowering personalized medicine initiatives.
  • Clinical Routine: Offering reliable, AI-powered tools for everyday pathological assessments.

“Mindpeak’s established product portfolio of clinical AI algorithms, which currently supports pathologists in assessing immunohistochemistry (IHC), hematoxylin and eosin (H&E) stained slides, will be extended to mIF in this promising partnership,” says Felix Faber, CEO at Mindpeak. “We are thrilled to combine our expertise in AI pathology with ZEISS’s instrumentation to create a streamlined workflow from slide to report for our customers.”

A Burgeoning Partnership

The partnership combines complementary competencies and expands both companies’ reach in the growing mIF market, the companies say. Zeiss and Mindpeak made their first joint appearance at the ESSB (European Society for Molecular Biomarkers) Conference in Berlin, showcasing the new mIF solution to pathologists and researchers. Additional details will be shared as the development of the platform progresses.

Further Reading

ZEISS’ New Software Improves Laser Scanning Microscopes

“At ZEISS, we are committed to driving innovation in imaging solutions that bridge the gap between research and clinical applications. This collaboration with Mindpeak marks a significant milestone in advancing workflows for translational and clinical pathology,” says Michael Albiez, head of Zeiss Research Microscopy Solutions.”Together, we are introducing an integrated solution that streamlines mIF workflows and improves reproducibility to meet the evolving needs of both translational research and clinical settings. By combining ZEISS’ imaging expertise with Mindpeak’s AI-driven analytics, we aim to enable researchers and clinicians to gain deeper insights with greater efficiency and precision.”